Cargando…

In vitro Dynamic Pharmacokinetic/Pharamcodynamic (PK/PD) study and CO(PD) of Marbofloxacin against Haemophilus parasuis

BACKGROUND: Haemophilus parasuis (H. parasuis) can invade the body and cause systemic infection under stress conditions. Marbofloxacin has been recommended for the treatment of swine infections. However, few studies have investigated the PK/PD characteristics and PK/PD cutoff (CO(PD)) of this drug a...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Jian, Xiao, Xia, Huang, Rui-Juan, Yang, Tao, Chen, Yi, Fang, Xi, Huang, Ting, Zhou, Yu-Feng, Liu, Ya-Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4666160/
https://www.ncbi.nlm.nih.gov/pubmed/26626889
http://dx.doi.org/10.1186/s12917-015-0604-5
_version_ 1782403671237066752
author Sun, Jian
Xiao, Xia
Huang, Rui-Juan
Yang, Tao
Chen, Yi
Fang, Xi
Huang, Ting
Zhou, Yu-Feng
Liu, Ya-Hong
author_facet Sun, Jian
Xiao, Xia
Huang, Rui-Juan
Yang, Tao
Chen, Yi
Fang, Xi
Huang, Ting
Zhou, Yu-Feng
Liu, Ya-Hong
author_sort Sun, Jian
collection PubMed
description BACKGROUND: Haemophilus parasuis (H. parasuis) can invade the body and cause systemic infection under stress conditions. Marbofloxacin has been recommended for the treatment of swine infections. However, few studies have investigated the PK/PD characteristics and PK/PD cutoff (CO(PD)) of this drug against H. parasuis. RESULTS: MICs of marbofloxacin against 198 H. parasuis isolates were determined. The MIC(50) and MIC(90) were 2 and 8 mg/L, respectively. An in vitro dynamic PK/PD model was established to study the PK/PD relationship of marbofloxacin against H. parasuis. The PK/PD surrogate markers C(max)/MIC, C(max)/MPC (the maximum concentration divided by MIC or mutant prevention concentration (MPC)) and AUC(24h)/MIC, AUC(24h)/MPC (the area under the curve during the first 24 h divided by MIC or MPC) simulated the antimicrobial effect of marbofloxacin successfully with the R(2) of 0.9928 and 0.9911, respectively. The target values of 3-log(10)-unit and 4-log(10)-unit reduction for AUC(24h)/MPC were 33 and 42, while the same efficacy for AUC(24h)/MIC were 88 and 110. The CO(PD) deduced from Monte Carlo simulation (MCS) for marbofloxacin against H. parasuis was 0.5 mg/L. The recommended dose of marbofloxacin against H. parasuis with MIC ≤ 2 mg/L was 16 mg/kg body weight (BW). CONCLUSIONS: The PK/PD surrogate markers AUC(24h)/MIC, C(max)/MIC and AUC(24h)/MPC, C(max)/MPC properly described the effects of marbofloxacin. Marbofloxacin can achieve the best efficacy at dosage of 16 mg/kg BW for strains with MIC values ≤ 2 mg/L, therefore, it is obligatory to know the sensitivity of the pathogen and to treat animals as early as possible. The very first CO(PD) provide fundamental data for marbofloxacin breakpoint determination.
format Online
Article
Text
id pubmed-4666160
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46661602015-12-02 In vitro Dynamic Pharmacokinetic/Pharamcodynamic (PK/PD) study and CO(PD) of Marbofloxacin against Haemophilus parasuis Sun, Jian Xiao, Xia Huang, Rui-Juan Yang, Tao Chen, Yi Fang, Xi Huang, Ting Zhou, Yu-Feng Liu, Ya-Hong BMC Vet Res Research Article BACKGROUND: Haemophilus parasuis (H. parasuis) can invade the body and cause systemic infection under stress conditions. Marbofloxacin has been recommended for the treatment of swine infections. However, few studies have investigated the PK/PD characteristics and PK/PD cutoff (CO(PD)) of this drug against H. parasuis. RESULTS: MICs of marbofloxacin against 198 H. parasuis isolates were determined. The MIC(50) and MIC(90) were 2 and 8 mg/L, respectively. An in vitro dynamic PK/PD model was established to study the PK/PD relationship of marbofloxacin against H. parasuis. The PK/PD surrogate markers C(max)/MIC, C(max)/MPC (the maximum concentration divided by MIC or mutant prevention concentration (MPC)) and AUC(24h)/MIC, AUC(24h)/MPC (the area under the curve during the first 24 h divided by MIC or MPC) simulated the antimicrobial effect of marbofloxacin successfully with the R(2) of 0.9928 and 0.9911, respectively. The target values of 3-log(10)-unit and 4-log(10)-unit reduction for AUC(24h)/MPC were 33 and 42, while the same efficacy for AUC(24h)/MIC were 88 and 110. The CO(PD) deduced from Monte Carlo simulation (MCS) for marbofloxacin against H. parasuis was 0.5 mg/L. The recommended dose of marbofloxacin against H. parasuis with MIC ≤ 2 mg/L was 16 mg/kg body weight (BW). CONCLUSIONS: The PK/PD surrogate markers AUC(24h)/MIC, C(max)/MIC and AUC(24h)/MPC, C(max)/MPC properly described the effects of marbofloxacin. Marbofloxacin can achieve the best efficacy at dosage of 16 mg/kg BW for strains with MIC values ≤ 2 mg/L, therefore, it is obligatory to know the sensitivity of the pathogen and to treat animals as early as possible. The very first CO(PD) provide fundamental data for marbofloxacin breakpoint determination. BioMed Central 2015-12-01 /pmc/articles/PMC4666160/ /pubmed/26626889 http://dx.doi.org/10.1186/s12917-015-0604-5 Text en © Sun et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Sun, Jian
Xiao, Xia
Huang, Rui-Juan
Yang, Tao
Chen, Yi
Fang, Xi
Huang, Ting
Zhou, Yu-Feng
Liu, Ya-Hong
In vitro Dynamic Pharmacokinetic/Pharamcodynamic (PK/PD) study and CO(PD) of Marbofloxacin against Haemophilus parasuis
title In vitro Dynamic Pharmacokinetic/Pharamcodynamic (PK/PD) study and CO(PD) of Marbofloxacin against Haemophilus parasuis
title_full In vitro Dynamic Pharmacokinetic/Pharamcodynamic (PK/PD) study and CO(PD) of Marbofloxacin against Haemophilus parasuis
title_fullStr In vitro Dynamic Pharmacokinetic/Pharamcodynamic (PK/PD) study and CO(PD) of Marbofloxacin against Haemophilus parasuis
title_full_unstemmed In vitro Dynamic Pharmacokinetic/Pharamcodynamic (PK/PD) study and CO(PD) of Marbofloxacin against Haemophilus parasuis
title_short In vitro Dynamic Pharmacokinetic/Pharamcodynamic (PK/PD) study and CO(PD) of Marbofloxacin against Haemophilus parasuis
title_sort in vitro dynamic pharmacokinetic/pharamcodynamic (pk/pd) study and co(pd) of marbofloxacin against haemophilus parasuis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4666160/
https://www.ncbi.nlm.nih.gov/pubmed/26626889
http://dx.doi.org/10.1186/s12917-015-0604-5
work_keys_str_mv AT sunjian invitrodynamicpharmacokineticpharamcodynamicpkpdstudyandcopdofmarbofloxacinagainsthaemophilusparasuis
AT xiaoxia invitrodynamicpharmacokineticpharamcodynamicpkpdstudyandcopdofmarbofloxacinagainsthaemophilusparasuis
AT huangruijuan invitrodynamicpharmacokineticpharamcodynamicpkpdstudyandcopdofmarbofloxacinagainsthaemophilusparasuis
AT yangtao invitrodynamicpharmacokineticpharamcodynamicpkpdstudyandcopdofmarbofloxacinagainsthaemophilusparasuis
AT chenyi invitrodynamicpharmacokineticpharamcodynamicpkpdstudyandcopdofmarbofloxacinagainsthaemophilusparasuis
AT fangxi invitrodynamicpharmacokineticpharamcodynamicpkpdstudyandcopdofmarbofloxacinagainsthaemophilusparasuis
AT huangting invitrodynamicpharmacokineticpharamcodynamicpkpdstudyandcopdofmarbofloxacinagainsthaemophilusparasuis
AT zhouyufeng invitrodynamicpharmacokineticpharamcodynamicpkpdstudyandcopdofmarbofloxacinagainsthaemophilusparasuis
AT liuyahong invitrodynamicpharmacokineticpharamcodynamicpkpdstudyandcopdofmarbofloxacinagainsthaemophilusparasuis